Scientists at NASA's Marshall Space Flight Center have accurately predicted the current phase of Cycle 23 of the sunspot cycle. The team predicts that Cycle 23 will be above average but not a record setter, with the sun now on the upswing of its 23rd activity cycle.
SourceNASA/Marshall Space Flight Center--Space Sciences Laboratory·DateOct 19, 1998
Researchers from the University of Michigan, Northwestern University, University of Minnesota, and University of Wisconsin have formed a virtual center to facilitate collaboration. This innovation uses collaborative tools and technology to enable researchers to work together as if they were in the same location.
Deep Space 1, a miniaturized space probe powered by solar-electric propulsion, will navigate through space and analyze charged particles and magnetic fields surrounding an asteroid and two comets. The mission, led by CU-Boulder Professor Fran Bagenal, tests innovative technologies and aims to explore the outer solar system.
Sony Alpha a7 IV (Body Only)
Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.
Researchers at UNC-CH found that Pamidronate is highly effective in partially reversing bone loss caused by immuno-suppressant drugs after lung transplants. Patients treated with the drug experienced a 10% reversal of bone loss, and showed significant increases in femur and spine mineral densities.
SourceUniversity of North Carolina at Chapel Hill·DateOct 19, 1998
The Women's Health Initiative has reached its recruitment goal for a 15-year study examining the causes of death, disability and frailty in post-menopausal women. The clinical trial involves 68,000 women studying estrogen and progestin effects on heart disease and breast cancer.
SourceNIH/National Heart, Lung and Blood Institute·DateOct 19, 1998
Researchers have successfully tested an implantable device called Atrioverter to treat atrial fibrillation, a condition that can lead to stroke. The device restored normal rhythm in 96% of treated individuals, offering a new treatment option for those prone to irregular heartbeats.
SourceAmerican Heart Association·JournalJournal of the American Heart Association·DateOct 19, 1998